Aethlon Medical, Inc. - 10-Q Summary (Period Ended September 30, 2008)
Business Context and Reporting Period
Aethlon Medical, Inc. is a development-stage medical device company focused on the Hemopurifier(R) platform, designed to remove viruses and toxins from human blood. The company has not generated significant revenue from principal operations and is classified as a development-stage enterprise. This report covers the quarterly period ended September 30, 2008, and the six-month period ended on that date.
Key Financial Metrics
| Metric | Six Months Ended Sep 30, 2008 | Six Months Ended Sep 30, 2007 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Expenses | $1,356,318 | $1,561,301 |
| Net Loss | $(2,811,635) | $(791,251) |
| Loss Per Share (Basic/Diluted) | $(0.07) | $(0.02) |
| Cash at Period End | $0 | $180,146 |
| Net Cash Used in Operating Activities | $(1,174,998) | $(1,067,242) |
| Total Current Liabilities | $4,194,342 | $3,810,369 |
| Working Capital | $(4,157,519) | $(3,480,939) |
| Accumulated Deficit | $(35,038,891) | $(32,227,256) |
Material Changes vs. Prior Period
- Liquidity Crisis: Cash reserves were depleted to $0 by September 30, 2008, down from $254,691 at the start of the fiscal year (March 31, 2008).
- Increased Net Loss: The net loss for the six-month period increased significantly to $2.81 million from $0.79 million in the prior year period. This was driven primarily by a $607,908 loss on the settlement of accrued interest and damages and a substantial increase in interest expense due to the amortization of debt discounts.
- Debt Defaults: The company is in default on various debt instruments, including $352,500 in past-due notes and the Amended Series A Convertible Notes due to failure to register warrants and make interest payments.
- Operating Expenses: Total operating expenses decreased by approximately 13% compared to the prior six-month period, largely due to a reduction in non-cash stock-based compensation.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised significant doubt about the company's ability to continue as a going concern. Current resources are insufficient to fund operations for the fiscal year ending March 31, 2009.
- Capital Needs: The company requires a minimum of $186,000 per month to sustain operations and is actively seeking additional funds through debt or equity financing. Failure to secure capital could force the company to curtail operations, sell technology, or cease operations.
- Regulatory Status: The company is seeking FDA approval to initiate clinical trials for the Hemopurifier(R). No assurance exists that the device will be cleared for marketing.
- Debt Settlements: To address defaults, the company has been converting accrued debt and interest into common stock and warrants. In September 2008, a registration statement was declared effective, halting the accrual of liquidated damages on certain notes.
Investor Verification Checklist
- Cash Runway: Verify the status of current cash reserves and the timeline for any pending financing rounds, given the $0 cash balance.
- Debt Negotiations: Confirm the status of negotiations regarding the extension or waiver of defaulted notes totaling over $350,000 plus accrued interest.
- Dilution Risk: Assess the impact of recent and potential future equity issuances used to settle debt and fund operations on existing shareholders.
- Regulatory Milestones: Monitor the progress of the Investigational Device Exemption (IDE) and the timeline for FDA approval of clinical trials.
- Going Concern Opinion: Review the auditor's assessment regarding the company's ability to meet obligations for the next 12 months.